Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07227415 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

A Phase 1 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
224
Enrollment target
14
Study locations

NCT07227415: Recruiting Phase 1 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, sponsored by Pfizer.

NCT07227415 is a Phase 1 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 224 participants, above the 198-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (13% higher). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07227415, a Phase 1 study of Clear Cell Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
224 participants
Enrollment target
14
Study locations

Study Summary

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

Primary Outcome

ORR is defined as the proportion of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1 as assessed by investigator.

Conditions Studied

Clear Cell Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Carcinoma, Renal Cell Renal Cancer Advanced Renal Cell Carcinoma Renal Neoplasm Clear-cell Metastatic Renal Cell Carcinoma Carcinoma, Renal Cell Metastasis Advanced or Metastatic Renal Cell Carcinoma Carcinoma, Renal Cell, Advanced

Interventions

  • BIOLOGICAL PF-08634404
  • DRUG Combination 1
  • DRUG Combination 2

Study Locations (14)

Texas

  • Texas Oncology - Central South - Austin
  • Texas Oncology - Gulf Coast - Houston

Virginia

  • Virginia Cancer Specialists, PC - Fairfax
  • Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care - Wytheville

Other

  • National Hospital Organization Kyushu Cancer Center - Fukuoka
  • Yamagata University Hospital - Yamagata

Arkansas

  • Highlands Oncology Group - Springdale

California

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte

Colorado

  • Rocky Mountain Cancer Centers, LLP - Denver

Illinois

  • City Of Hope - Chicago - Zion

Minnesota

  • Minnesota Oncology Hematology, P.A. - Minneapolis

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2026-02-10
Est. Completion 2028-11-01
Phase Phase 1
Pfizer

1,845 total trials

What NCT07227415 shows while recruiting

NCT07227415 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, above the 198-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (13% higher).

The record links to 10 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which PF-08634404 is the first listed.

NCT07227415 lists 14 locations in 11 states (Texas, Virginia, Other).

Frequently Asked Questions

What is clinical trial NCT07227415 about?

NCT07227415 is a clinical study titled "A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer". This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the ...

What is the current status of trial NCT07227415?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2026-02-10. Estimated completion is 2028-11-01.

What conditions does trial NCT07227415 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Renal Cancer, Advanced Renal Cell Carcinoma.

What interventions are being tested in trial NCT07227415?

The interventions under investigation include: PF-08634404 (BIOLOGICAL), Combination 1 (DRUG), Combination 2 (DRUG).

Who is sponsoring clinical trial NCT07227415?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07227415 being conducted?

This trial has 14 study locations across Arkansas, California, Colorado, Illinois, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07227415's enrollment target sits among peer trials

224 9th of 45 higher than 37 of 45 other Clear Cell Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02706561 · 224 participants · NA

    Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

  • NCT04140344 · 224 participants · NA

    The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions

  • NCT04915183 · 224 participants · Phase 2

    Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

  • NCT05519878 · 224 participants · NA

    Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07227415

Source: ClinicalTrials.gov NCT07227415, the US trial registry maintained by the National Library of Medicine. NCT07227415 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.